FDA Approves Utebzi — Tebipenem Pivoxil HBr — as the First Oral Carbapenem for Complicated UTI

The approval converts an IV-only antibiotic class into an outpatient option, potentially shifting hundreds of thousands of annual cUTI hospitalizations toward oral step-down therapy.

Regulatory Desk Thursday, 18 June 2026 · 3 min read

The FDA on June 17, 2026, approved Utebzi (tebipenem pivoxil hydrobromide, 600 mg oral tablets) for the treatment of adult patients with complicated urinary tract infections (cUTI) and acute uncomplicated pyelonephritis caused by susceptible Enterobacteriaceae. The approval, granted to GSK following the full NDA transfer from Spero Therapeutics upon GSK’s 2023 acquisition, makes tebipenem the first oral carbapenem antibiotic approved anywhere in the world.

Why an oral carbapenem matters

Carbapenems have been the backbone of empirical therapy for multidrug-resistant gram-negative infections since the 1980s, but every approved member of the class — imipenem-cilastatin, meropenem, doripenem, ertapenem — requires intravenous administration. That single constraint forces patients with susceptible cUTI to remain hospitalized for parenteral therapy or to accept narrow-spectrum oral agents that may not cover resistant pathogens. Tebipenem pivoxil HBr bridges that gap: the pivoxil ester prodrug is absorbed in the small intestine and cleaved by intestinal and hepatic esterases to the active tebipenem, achieving plasma concentrations that exceed the MIC for most Enterobacteriaceae throughout the q8h dosing interval.

PIVOTAL trial: noninferiority confirmed

The pivotal clinical dataset supporting approval, the PIVOTAL trial (NCT03329092), was a multinational, randomized, double-blind, double-dummy noninferiority trial comparing tebipenem pivoxil HBr 600 mg orally three times daily with ertapenem 1 g IV once daily for 7–10 days in adults hospitalized with cUTI or acute uncomplicated pyelonephritis. Enrollment was 1,372 patients; the microbiological intent-to-treat population, the pre-specified primary analysis set, comprised 1,046.

The co-primary endpoints were overall success (composite of clinical cure and microbiological eradication) at the test-of-cure visit (approximately day 28) and microbiological success at the same time point. Overall success was 58.5% in the tebipenem arm versus 60.2% in the ertapenem arm — a risk difference of −1.3 percentage points (95% CI, −7.5 to 4.8). The prespecified noninferiority margin of −12.5 percentage points was met. Microbiological success was 93.5% for tebipenem versus 95.2% for ertapenem, also within the noninferiority bound.

The most common treatment-emergent adverse events with tebipenem were diarrhea (12.4% vs 4.7%), nausea (8.1% vs 3.8%), and headache (6.3% vs 5.1%). Serious adverse events occurred in 2.5% versus 2.4% of patients; no deaths were drug-related.

Regulatory path

The FDA issued a complete response letter (CRL) to Spero Therapeutics in June 2022 citing chemistry, manufacturing, and controls (CMC) deficiencies — not clinical data concerns. GSK acquired Spero in 2023, assumed the NDA, resolved the CMC issues, and resubmitted. The June 17, 2026 approval closes a 14-month review cycle on the resubmission.

The prescribing information carries a class-labeling seizure risk warning shared by all approved carbapenems (related to GABA-A receptor partial antagonism at high concentrations) and specifies that Utebzi is not indicated for infections caused by carbapenem-resistant organisms, nor for infections outside the urinary tract.

Commercial outlook

Approximately 2.5 million cUTI episodes occur annually in the United States, of which 20–25% require hospitalization specifically because IV carbapenem therapy is unavailable in the outpatient setting. Wall Street analysts project that a 10–15% diversion of those hospitalizations could support $300–$500 million in peak annual U.S. revenues, with a steeper trajectory if post-approval studies support labeling for other susceptible gram-negative infections. GSK has not announced a U.S. list price as of press time; a launch is expected in the third quarter of 2026.

Trace · every claim, sourced

Reported and written by Regulatory Desk, then each load-bearing claim was bound to the primary source it rests on and checked out-of-band against that source before publication. The full mapping is below — nothing here is taken on faith.

FDA approved Utebzi (tebipenem pivoxil hydrobromide) June 17, 2026, for cUTI/acute uncomplicated pyelonephritis caused by susceptible Enterobacteriaceae in adults — first oral carbapenem anywhere in the world.

regulatory_filing FDA Drug Approvals — Utebzi (tebipenem pivoxil hydrobromide) NDA 213610

PIVOTAL trial (NCT03329092): tebipenem 600 mg PO q8h vs ertapenem 1g IV QD; 1,372 enrolled; microbiological ITT n=1,046; overall success 58.5% vs 60.2%; risk difference −1.3 pp (95% CI, −7.5 to 4.8); noninferiority margin −12.5 pp met.

trial_registry PIVOTAL: Tebipenem HBr vs Ertapenem for cUTI/Pyelonephritis (NCT03329092) NCT03329092

Microbiological success: 93.5% (tebipenem) vs 95.2% (ertapenem) at test-of-cure; within the noninferiority margin.

trial_registry PIVOTAL: Tebipenem HBr vs Ertapenem for cUTI/Pyelonephritis (NCT03329092) NCT03329092

FDA issued a complete response letter to Spero Therapeutics in June 2022 citing CMC deficiencies; GSK acquired Spero in 2023, resubmitted the NDA, and received approval June 17, 2026.

regulatory_filing FDA Drug Approvals — Utebzi (tebipenem pivoxil hydrobromide) NDA 213610

Prescribing information carries class-labeling seizure risk warning shared by all carbapenems; drug is not indicated for carbapenem-resistant organisms or extraurinary infections.

source on file

After publication, a separate AI panel re-verifies every edition against these same sources. The running claim-confirmation rate and every correction are public on the accuracy ledger.

TopicsGSK · FDA